The clinical evidence on drug efficacy and effectiveness is constantly expanding and it can be a challenge to keep track and visualize the clinical landscape. Certara’s CODEx and clinical trial outcomes databases change all of that.

CODEx is a smart combination of incredibly detailed databases and a state-of-the art exploratory tool to visualize the intricacies of literature data. CODEx provides not only a wealth of information, but also the resources to maximize the value of the information.

Below are the CODEx databases that we have curated for immunology.  Don’t hesitate to contact us if you would like a demo or a price quote.

Ankylosing Spondylitis

Contains summary level endpoint data from 66 studies reported in 123 references. The 5 most commonly reported efficacy and biomarker endpoints are asas20 (62 studies), basdai (52 studies), asas40 (50 studies), basfi (50 studies), and crp (42 studies).

Asthma

Contains summary level endpoint data from 37 studies reported in 52 references. The 5 most commonly reported efficacy and biomarker endpoints are eosinophils (27 studies), fev1 (26 studies), exacerbation rates (24 studies), exacerbations (22 studies), and aqlq (21 studies).

Atopic Dermatitis

Contains summary level endpoint data from 47 studies reported in 75 references. The 5 most commonly reported efficacy and biomarker endpoints are easi (37 studies), iga responders (30 studies), easi50 (29 studies), easi75 (29 studies), and bsa (26 studies).

Crohn's Disease

Contains summary level endpoint data from 127 studies reported in 191 references. The 5 most commonly reported efficacy and biomarker endpoints are clinical remission (110 studies), clinical response (96 studies), cdai score (71 studies), c-reactive protein (63 studies), and ibdq score (55 studies).

Cystic Fibrosis

Contains summary level endpoint data from 35 studies reported in 38 references. The 5 most commonly reported efficacy and biomarker endpoints are ppfev1 (34 studies), sweat chloride (30 studies), cfq-r respiratory symptoms (28 studies), fev1 (15 studies), and bmi (13 studies).

Multiple Sclerosis

Contains summary level endpoint data from 203 studies reported in 331 references. The 5 most commonly reported efficacy and biomarker endpoints are edss (140 studies), arr (117 studies), t1gd (105 studies), relapse free (103 studies), and t2 (99 studies).

Sjorgen's Syndrome

Contains summary level endpoint data from 33 studies reported in 39 references. The 5 most commonly reported efficacy and biomarker endpoints are schirmer i test (16 studies), unstimulated salivary flow (15 studies), esr (12 studies), stimulated salivary flow (12 studies), and igg (11 studies).

Ulcerative Colitis

Contains summary level endpoint data from 143 studies reported in 222 references. The 5 most commonly reported efficacy and biomarker endpoints are clinical remission (106 studies), clinical response (75 studies), mucosal healing (64 studies), endoscopic remission (56 studies), and symptomatic remission (46 studies).
COVID-19 Clinical Outcomes Database

The COVID-19 Clinical Outcomes Database was developed to document clinical safety and efficacy information from studies investigating treatments and emerging interventions. It captures all important aspects of reference information, study design, patient population characteristics, randomized and concomitant treatments, statistical analyses and results.

The complete Quantify COVID-19 Clinical Outcomes Database contains summary level endpoint data from 55 studies reported in 50 references. The 5 most commonly reported efficacy endpoints are death (46 studies), critical disease (34 studies), hospitalization discharge (30 studies), hospitalization (28 studies), and lymphocytes (25 studies).

Get a quote
Psoriasis Clinical Outcomes Database

The CODEx Psoriasis Clinical Outcomes Database was developed to document clinical safety and efficacy information from studies investigating treatments and emerging interventions. It captures all important aspects of reference information, study design, patient population characteristics, randomized and concomitant treatments, statistical analyses and results.

The complete database contains summary level endpoint data from 185 studies reported in 390 references. The 5 most commonly reported efficacy and biomarker endpoints are PASI75 (171 studies), PASI score (156 studies), PASI90 (145 studies), physician global assessment <=1 (136 studies), and PASI50 (110 studies).

Contact us
Rheumatoid Arthritis Clinical Outcomes Database

The CODEx Rheumatoid Arthritis database was developed to document clinical safety and efficacy information from studies investigating treatments and emerging interventions. It captures all important aspects of reference information, study design, patient population characteristics, randomized and concomitant treatments, statistical analyses and results.

The complete database contains summary level endpoint data from 305 studies reported in 647 references. The 5 most commonly reported efficacy and biomarker endpoints are ACR20 (273 studies), ACR50 (262 studies), swollen joint count (262 studies), HAQ (261 studies), and tender joint count (260 studies).

Download brochure